Substituted 2-aminotetralins
AssigneeWhitby Research, Inc.
InventorAlan S. Horn
Life of this patent
Estimating the term…
Abstract
Certain novel compounds having the structural formula ##STR1## wherein R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of H and OA; A is H or is selected from the group consisting of hydrocarbyl radicals, e.g. lower alkyl radicals, i.e. methyl, ethyl, propyl, etc., or ##STR2## wherein R.sub.5 is selected from the group consisting of hydrocarbyl radicals, e.g. alkyl and aromatic residues; n is 2 or 3; and R.sub.1 is selected from the group consisting of organic radicals having fused aromatic rings, that is, radicals comprising at least two rings that share a pair of carbon atoms or share a carbon and nitrogen atom are useful for inducing a dopaminergic response and reducing the intraocular pressure in a mammal.
Claims24
Optically active or racemic compounds having the general formula:
- ##STR11## wherein R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of H and OA;
- A is selected from the group consisting of hydrogen hydrocarbyl radicals, and radicals represented by the general formula --C(O)--R.sub.5, wherein R.sub.5 is selected from the group consisting of hydrocarbyl radicals, n is 2 or 3 and R.sub.1 is selected from the group consisting of naphthyl, anthracyl, phenanthryl, and substituted derivatives thereof wherein the substituents have no more than 12 carbon atoms and are selected from the group consisting of hydroxy, nitro, azido, sulfonamido, sulfate, halogen, hydrocarbon and heteratom-substituted hydrocarbon wherein said heteratoms are selected from the group consisting of halogen, nitrogen, sulfur and phosphorus;
- and wherein at least one of R.sub.2, R.sub.3 and R.sub.4 is H, and at least one of R.sub.2, R.sub.3 and R.sub.4 is not H, and R.sub.2 and R.sub.4 are not both OA and pharmaceutically-acceptable salts thereof.
A composition for reducing the intraocular pressure in mammals which comprises an effective amount of a compound selected from the group consisting of compounds having the structural formula:
- ##STR13## wherein R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of H and OA;
- A is selected from the group consisting of hydrogen, hydrocarbyl radicals, and radicals represented by the general formula --C(O)--R.sub.5, wherein R.sub.5 is selected from the group consisting of hydrocarbyl radicals, n is 2 or 3 and R.sub.1 is selected from the group consisting of naphthyl, anthracyl, phenanthryl, and substituted derivatives thereof wherein the substituents have no more than 12 carbon atoms and are selected from the group consisting of hydroxy, nitro, azido, sulfonamido, sulfate, halogen, hydrocarbon and heteratom-substituted hydrocarbon wherein said heteratoms are selected from the group consisting of halogen, nitrogen, sulfur and phosphorus;
- and wherein at least one of R.sub.2, R.sub.3 and R.sub.4 is H, and at least one of R.sub.2, R.sub.3 and R.sub.4 is not H, and R.sub.2 and R.sub.4 are not both OA and pharmaceutically-acceptable salts thereof, and an ophthalmic carrier for said compound.
A method for reducing the intraocular pressure in mammals which comprises administering an effective amount of a compound selected from the group consisting of compounds represented by the general formula:
- ##STR15## wherein R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of H and OA;
- A is selected from the group consisting of hydrogen, hydrocarbyl radicals, and radicals represented by the general formula --C(O)--R.sub.5, wherein R.sub.5 is selected from the group consisting of hydrocarbyl radicals, n is 2 or 3 and R.sub.1 is selected from the group consisting of naphthyl, anthracyl, phenanthryl, and substituted derivatives thereof wherein the substituents have no more than 12 carbon atoms and are selected from the group consisting of hydroxy, nitro, azido, sulfonamido, sulfate, halogen, hydrocarbon and heteratom-substituted hydrocarbon wherein said heteratoms are selected from the group consisting of halogen, nitrogen, sulfur and phosphorus;
- and wherein at least one of R.sub.2, R.sub.3 and R.sub.4 is H, and at least one of R.sub.2, R.sub.3 and R.sub.4 is not H, and R.sub.2 and R.sub.4 are not both OA and pharmaceutically-acceptable salts thereof.
A method comprising inducing a dopaminergic response in a patient by administering a pharmacologically-effective amount of a compound represented by the general formula:
- ##STR17## wherein R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of H and OA;
- A is selected from the group consisting of hydrogen, hydrocarbyl radicals, and radicals represented by the general formula --C(O)--R.sub.5, wherein R.sub.5 is selected from the group consisting of hydrocarbyl radicals, n is 2 or 3 and R.sub.1 is selected from the group consisting of naphthyl, anthracyl, phenanthryl, and substituted derivatives thereof wherein the substituents have no more than 12 carbon atoms and are selected from the group consisting of hydroxy, nitro, azido, sulfonamido, sulfate, halogen, hydrocarbon and heteratom-substituted hydrocarbon wherein said heteratoms are selected from the group consisting of halogen, nitrogen, sulfur and phosphorus;
- and wherein at least one of R.sub.2, R.sub.3 and R.sub.4 is H, and at least one of R.sub.2, R.sub.3 and R.sub.4 is not H, and R.sub.2 and R.sub.4 are not both OA and pharmaceutically-acceptable salts thereof.
Dependencies are inferred from the claim text.